726 related articles for article (PubMed ID: 34691042)
61. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
62. Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors.
Dowell AC; Haigh TA; Ryan GB; Turner JE; Long HM; Taylor GS
PLoS Pathog; 2021 Dec; 17(12):e1010137. PubMed ID: 34882759
[TBL] [Abstract][Full Text] [Related]
63. Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.
Greijer AE; Stevens SJ; Verkuijlen SA; Juwana H; Fleig SC; Verschuuren EA; Hepkema BG; Cornelissen JJ; Brooimans RA; Verdonck LF; Middeldorp JM
Clin Dev Immunol; 2012; 2012():543085. PubMed ID: 23346186
[TBL] [Abstract][Full Text] [Related]
64. Epstein-Barr Virus gH/gL and Kaposi's Sarcoma-Associated Herpesvirus gH/gL Bind to Different Sites on EphA2 To Trigger Fusion.
Chen J; Schaller S; Jardetzky TS; Longnecker R
J Virol; 2020 Oct; 94(21):. PubMed ID: 32847853
[TBL] [Abstract][Full Text] [Related]
65. A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
Li F; Freed D; Heidecker G; Galli J; Durr E; Wang D
Vaccine; 2022 Jun; 40(26):3638-3646. PubMed ID: 35577627
[TBL] [Abstract][Full Text] [Related]
66. Non-viral
Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
[TBL] [Abstract][Full Text] [Related]
67. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
Ning RJ; Xu XQ; Chan KH; Chiang AK
Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
[TBL] [Abstract][Full Text] [Related]
68. Epstein-Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV.
Kim J; Bu W; Mine S; Tariq Z; Nguyen H; Wang Y; Tolman C; Mond J; Cohen JI
Virology; 2021 Sep; 561():80-86. PubMed ID: 34171765
[TBL] [Abstract][Full Text] [Related]
69. The promise of a prophylactic Epstein-Barr virus vaccine.
Balfour HH; Schmeling DO; Grimm-Geris JM
Pediatr Res; 2020 Jan; 87(2):345-352. PubMed ID: 31641280
[TBL] [Abstract][Full Text] [Related]
70. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
Smith NA; Coleman CB; Gewurz BE; Rochford R
J Virol; 2020 May; 94(11):. PubMed ID: 32238579
[TBL] [Abstract][Full Text] [Related]
71. An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.
Snijder J; Ortego MS; Weidle C; Stuart AB; Gray MD; McElrath MJ; Pancera M; Veesler D; McGuire AT
Immunity; 2018 Apr; 48(4):799-811.e9. PubMed ID: 29669253
[TBL] [Abstract][Full Text] [Related]
72. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
73. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Léonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M
J Infect Dis; 2007 Dec; 196(12):1749-53. PubMed ID: 18190254
[TBL] [Abstract][Full Text] [Related]
74. A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge.
Edwards KR; Malhi H; Schmidt K; Davis AR; Homad LJ; Warner NL; Chhan CB; Scharffenberger SC; Gaffney K; Hinkley T; Potchen NB; Wang JY; Price J; McElrath MJ; Olson J; King NP; Lund JM; Moodie Z; Erasmus JH; McGuire AT
NPJ Vaccines; 2024 Jun; 9(1):120. PubMed ID: 38926438
[TBL] [Abstract][Full Text] [Related]
75. [The entry of Epstein-Barr virus into B lymphocytes and epithelial cells during infection].
Zuo LL; Zhu MJ; Du SJ; Lu JH; Li GY
Bing Du Xue Bao; 2014 Jul; 30(4):476-82. PubMed ID: 25272606
[TBL] [Abstract][Full Text] [Related]
76. Progress, prospects, and problems in Epstein-Barr virus vaccine development.
Balfour HH
Curr Opin Virol; 2014 Jun; 6():1-5. PubMed ID: 24632197
[TBL] [Abstract][Full Text] [Related]
77. Epstein-barr virus vaccines.
Cohen JI
Clin Transl Immunology; 2015 Jan; 4(1):e32. PubMed ID: 25671130
[TBL] [Abstract][Full Text] [Related]
78. A virus-like particle-based Epstein-Barr virus vaccine.
Ruiss R; Jochum S; Wanner G; Reisbach G; Hammerschmidt W; Zeidler R
J Virol; 2011 Dec; 85(24):13105-13. PubMed ID: 21994444
[TBL] [Abstract][Full Text] [Related]
79. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay.
Calarota SA; Chiesa A; Zelini P; Comolli G; Minoli L; Baldanti F
Immunology; 2013 Aug; 139(4):533-44. PubMed ID: 23560877
[TBL] [Abstract][Full Text] [Related]
80. EBV-related lymphomas: new approaches to treatment.
Kanakry JA; Ambinder RF
Curr Treat Options Oncol; 2013 Jun; 14(2):224-36. PubMed ID: 23549980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
